Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Targeted CNS Focus: Conduit Pharmaceuticals concentrates on developing treatments for central nervous system disorders with high unmet medical needs, allowing for specialized expertise and market positioning.
Advanced Clinical Pipeline: Their lead candidate, CDT001, is already in or poised for Phase 2 clinical trials, significantly de-risking the development timeline compared to preclinical assets.
Validated Asset Acquisition: The lead candidate CDT001 was licensed from AstraZeneca, indicating prior validation and extensive preclinical work by a major pharmaceutical company.
Risks
Clinical Trial Failures: Clinical trials may fail to demonstrate efficacy or safety, leading to abandonment of drug candidates and significant financial losses.
Regulatory Approval Uncertainty: The company may not obtain necessary regulatory approvals from health authorities like the FDA, preventing products from reaching the market.
Funding and Liquidity Concerns: Conduit Pharmaceuticals may require substantial additional capital to fund ongoing research and development, and future financing may not be available on favorable terms or at all.
Over a week ago
Jun 18, 8:42 AM
May 28, 4:44 PM
Apr 27, 12:20 PM
Apr 22, 6:08 AM
Apr 20, 1:20 PM
Mar 27, 9:40 AM
Mar 27, 9:30 AM
Mar 26, 7:50 PM
Mar 26, 9:12 AM
Mar 25, 8:20 AM
Mar 18, 8:43 AM
Mar 12, 8:32 AM
Mar 5, 8:37 AM
Feb 24, 8:34 AM
Feb 20, 8:33 AM
Jan 30, 6:05 AM
Jan 2, 8:37 AM
Nov 28, 9:03 AM
Oct 17, 8:34 AM